Cardio Diagnostics Holdings, Inc. (CDIO)
NASDAQ: CDIO · Real-Time Price · USD
3.900
-0.240 (-5.80%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.

The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management.

It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform.

It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations.

Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings logo
CountryUnited States
Founded2017
IndustryBiotechnology
SectorHealthcare
Employees15
CEOMeeshanthini Dogan

Contact Details

Address:
311 West Superior Street, Suite 444
Chicago, Illinois 60654
United States
Phone855 226 9991
Websitecdio.ai

Stock Details

Ticker SymbolCDIO
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001870144
CUSIP Number14159C103
ISIN NumberUS14159C1036
Employer ID87-0925574
SIC Code2835

Key Executives

NamePosition
Dr. Meeshanthini V. Dogan Ph.D.Co-Founder, Chief Executive Officer and Director
Elisa Michael Luqman Esq., J.D., M.B.A.Chief Financial Officer and Principal Accounting Officer
Timur Dogan Ph.D.Chief Technology Officer
Dr. Robert A. Philibert M.D., Ph.D.Co-Founder, Chief Medical Officer and Director
Khullani Abdullahi J.D.Vice President of Revenue and Strategy

Latest SEC Filings

DateTypeTitle
May 28, 20258-KCurrent Report
May 15, 202510-QQuarterly Report
May 13, 20258-KCurrent Report
Apr 8, 2025S-8Securities to be offered to employees in employee benefit plans
Mar 25, 2025424B3Prospectus
Mar 25, 2025424B3Prospectus
Mar 20, 202510-KAnnual Report
Feb 21, 20258-KCurrent Report
Feb 14, 2025EFFECTNotice of Effectiveness
Feb 14, 2025424B5Filing